Overweight and obesity are one of the most relevant health factors; according to the WHO,
39% of people globally are overweight and 13% obese. 1 Body weight loss of 3%–5% has …

Objective: The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …

Semaglutide 2· 4 mg once weekly, an anti-obesity medication now submitted to regulators
across the USA and Europe, is generating much excitement and attention about the amount …

Objective The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …

Global average data suggest that the prevalence of male obesity is increasing and that its
prevalence in some regions of Western Europe, Japan, China, Korea and USA is higher …

This past June, the US Food and Drug Administration approved semaglutide, a glucagon-
like peptide 1 receptor agonist marketed as Wegovy, for chronic weight management based …

Objective: To review the efficacy, safety, and role of the glucagon-like peptide-1 (GLP-1)
receptor agonist semaglutide for chronic weight management. Data Sources: A literature …

Obesity is a global health challenge. It is a multifactorial, complex, and progressive disease
associated with various health complications and increased mortality. Lifestyle modifications …

Over the long, checkered history of weight-loss drugs, a safe and highly effective medication
has been the elusive holy grail. The handful of drugs currently approved for long-term …

Driven by the recently reported shortages of semaglutide, both I and my colleagues sought
to introduce physicians to the current state of epidemiology, associated risks, and treatment …